Budget 2024 Boosts Biopharma Growth Without New Tax Incentives
The Union Budget 2024 has reinforced long-term growth prospects for India's biopharma sector through strategic initiatives, despite not introducing new tax incentives. Key measures include enhanced R&D funding and infrastructure development.